Precision proteomics companies race to commercialize blood-based disease detection

Overview

Updated May 31

Alamar Biosciences raised $191 million in its initial public offering on April 17, 2026 (nearly double the $100 million it originally planned) after investor demand exceeded available shares by more than tenfold. Shares priced at $17, opened at $22.60, and closed at $22.00, a 29% first-day gain that gave the company a market capitalization of roughly $1.53 billion. The Fremont, California company develops technology that detects proteins in blood at concentrations so low that conventional tests miss them entirely, potentially catching diseases years earlier than current methods allow. CEO and founder Yuling Luo told Reuters the company plans to use the proceeds to expand into cancer, cardiology, and other major disease areas. The company reported $74.2 million in revenue for fiscal year 2025 (nearly triple the year prior), creating a baseline for investors to measure future commercial growth.

The historic biotech listings day saw obesity-drug developer Kailera Therapeutics raise $625 million in its April 17 IPO (the largest since Moderna's $600 million raise in 2018), surging 63% on its first day. Analysts cited both offerings as evidence investor appetite for life sciences listings had returned, a reversal from 2021–2023 when three protein-analysis firms' valuations collapsed. Thermo Fisher Scientific's $3.1 billion acquisition of Olink in early 2024 and breakthroughs in blood-based Alzheimer's testing proved that protein detection could solve real clinical problems.

Why it matters

Blood tests that detect diseases before symptoms appear could shift medicine from treatment to prevention — if the technology proves out at scale.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$191M

IPO proceeds

Nearly double the originally planned $100 million raise

10x

Oversubscription ratio

Investor demand exceeded available shares by more than tenfold

$22.00

First-day close

Shares closed 29.4% above the $17 IPO price on April 17, giving Alamar a ~$1.53B market cap

$74.2M

FY2025 revenue

Full-year 2025 revenue, nearly triple the prior year — the baseline public investors will measure growth against

$3.1B

Olink acquisition price

Thermo Fisher's early 2024 purchase of competitor Olink set the valuation benchmark for the sector

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Tae Man Kim

Co-founder and Chief Executive Officer, Alamar Biosciences

NOTE: Research indicates the CEO and founder of Alamar Biosciences is Yuling Luo, not Tae Man Kim. This entry may be in error and should be reviewed against primary sources.

Yuling Luo

Founder, Chairman, and Chief Executive Officer, Alamar Biosciences

Led company through IPO and first day of public trading

Organizations Involved

Alamar Biosciences

Proteomics Technology Company

Newly public, trading on Nasdaq as ALMR; shares closed 29.4% above IPO price on first day, valuing company at ~$1.53 billion

Develops the NULISA ultra-sensitive protein detection platform and ARGO HT instrument system for research and translational diagnostics.

Thermo Fisher Scientific Inc.

Life Sciences Conglomerate

Major competitor after acquiring Olink

The world's largest life sciences tools company, which entered the proteomics platform market by acquiring Olink for $3.1 billion in 2024.

Standard BioTools (formerly Fluidigm)

Life Sciences Tools Company

Merged with SomaLogic, operates combined proteomics platform

Formed through the merger of Fluidigm and SomaLogic, combining mass cytometry with the SomaScan aptamer-based proteomics platform that measures over 11,000 proteins.

Timeline

January 2020 April 2026

12 events Latest: April 17th, 2026 · 5 months ago Showing 8 of 12

Tap a bar to jump to that date

April 2026
Alamar prices upsized IPO at $17 per share
Latest Corporate

Alamar Biosciences begins trading on Nasdaq under ticker ALMR after pricing 11.25 million shares at $17 each, raising $191 million — nearly double the originally planned $100 million — with more than 10x oversubscription.
April 17th, 2026
Kailera Therapeutics prices IPO the same day as Alamar, signaling biotech window reopening
Market

Obesity-drug developer Kailera Therapeutics launched its IPO alongside Alamar on April 17, 2026, with analysts citing both offerings as evidence that the biotech listings window had materially reopened after a multi-year drought.
April 17th, 2026
ALMR surges 29% on first day of Nasdaq trading
Market

Alamar Biosciences shares opened at $22.60 and closed at $22.00, a 29.4% gain above the $17 IPO price, giving the company a market capitalization of approximately $1.53 billion on its first trading day.
April 17th, 2026
Kailera Therapeutics raises $625M in largest biotech IPO since Moderna (2018)
Market

Obesity-drug developer Kailera Therapeutics raised $625 million and surged 63% on its Nasdaq debut (ticker: KLRA), making April 17, 2026 one of the most significant single days for biotech public listings in years.
April 17th, 2026
January 2025
Blood-based Alzheimer's tests reach clinical validation
Scientific

Multiple protein-based blood tests for Alzheimer's disease achieve over 90% accuracy, demonstrating that protein detection can solve urgent clinical problems and driving demand for proteomics platforms.
January 1st, 2025
June 2024
Tempus AI IPOs at $6.1B valuation
Market

Artificial intelligence-driven precision medicine company Tempus raises $410 million in its IPO, signaling renewed appetite for diagnostics companies on public markets.
June 1st, 2024
SomaLogic merges with Standard BioTools
Market

After its stock declined sharply from its SPAC debut, SomaLogic merges with Standard BioTools at a fraction of its original valuation.
June 1st, 2024
April 2024
FDA finalizes rule on laboratory-developed tests
Regulatory

The Food and Drug Administration issues a final rule phasing out enforcement discretion for laboratory-developed tests over four years, raising the regulatory bar for diagnostic companies.
April 1st, 2024
February 2024
Thermo Fisher completes Olink deal
Market

The acquisition closes, giving Thermo Fisher a competing proteomics platform with global distribution and established pharma relationships.
February 1st, 2024
October 2023
Thermo Fisher announces $3.1B Olink acquisition
Market

The world's largest life sciences tools company agrees to buy proteomics platform maker Olink for $3.1 billion in cash, validating the commercial potential of high-throughput protein detection.
October 1st, 2023
September 2021
SomaLogic goes public via SPAC
Market

Proteomics competitor SomaLogic lists at a $1.2 billion valuation through a special-purpose acquisition company, part of a wave of pre-revenue life science SPACs.
September 1st, 2021
January 2020
Alamar Biosciences founded
Corporate

Tae Man Kim and co-founders establish Alamar Biosciences in Fremont, California, to develop the NULISA ultra-sensitive protein detection technology.
January 1st, 2020

#timeline [x-show="expanded"] { display: revert !important; opacity: 1 !important; } #timeline .timeline-toggle-btn { display: none; }

Scenarios

Alamar becomes the independent standard in research proteomics

Possible

Discussed by: Life science tools analysts, biotech venture investors who backed the company

Alamar's NULISA platform gains traction in pharmaceutical and academic research labs, with instrument placements growing steadily and consumable revenue compounding. The company establishes itself as the leading independent alternative to Thermo Fisher's Olink platform, benefiting from researchers' preference for vendor diversity. Revenue reaches profitability-supporting levels within three to four years, and the company either sustains independence or attracts acquisition offers at a significant premium.

Acquisition target: a larger tools company buys Alamar

Possible

Discussed by: Investment banking analysts, precedent set by Thermo Fisher's Olink acquisition

Alamar's validated technology and public-market valuation make it an attractive acquisition target for life science tools companies seeking proteomics capabilities — particularly those that lost the Olink bidding to Thermo Fisher. Companies like Danaher, Agilent, or Bruker could move to acquire Alamar to compete with the Thermo Fisher-Olink combination, potentially at a premium to the IPO valuation.

Commercialization stalls as Thermo Fisher's distribution dominance squeezes independents

Possible

Discussed by: Skeptical biotech analysts, observers of prior proteomics company struggles (Seer, Nautilus, SomaLogic)

Alamar struggles to convert research interest into sustained instrument sales against Thermo Fisher's global sales force and established customer relationships. Consumable pull-through per instrument disappoints, and the company burns through its IPO proceeds without reaching profitability. The stock follows the trajectory of earlier proteomics IPOs — Seer, Nautilus, and SomaLogic all saw their valuations decline sharply within two years of listing.

Protein diagnostics break into routine clinical use, expanding the market for all players

Likely

Discussed by: Precision medicine advocates, clinical diagnostics analysts, Alzheimer's research community

Breakthroughs in blood-based disease detection — particularly Alzheimer's screening and multi-cancer early detection — drive protein diagnostics from research-only use into routine clinical practice. The total market expands dramatically beyond what any single company can serve, lifting all proteomics platforms. Alamar pivots from research-use-only to pursuing regulatory clearance for clinical diagnostic applications, which would require significant additional investment but open a much larger revenue opportunity.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

October 2018

Guardant Health IPO and liquid biopsy commercialization (2018)

Guardant Health, which developed blood-based cancer detection tests using circulating tumor DNA rather than proteins, went public at a $2.3 billion valuation. The company had the Guardant360 test in clinical use and a clear regulatory strategy.

Then

The stock more than tripled within a year as Guardant demonstrated rapid revenue growth from its liquid biopsy tests.

Now

Guardant secured Food and Drug Administration approval for Guardant360 CDx as a companion diagnostic and expanded into early cancer detection with its Shield test, validating the path from research tool to approved clinical diagnostic.

Why this matters now

Guardant's trajectory illustrates the playbook Alamar may follow: establish the platform in research, build clinical evidence, then pursue regulatory approval for diagnostic use. The key difference is that Guardant detected DNA fragments while Alamar detects proteins — a complementary approach that could prove more sensitive for certain cancer types.

September 2021 - 2024

SomaLogic SPAC listing and decline (2021-2024)

SomaLogic, which developed the SomaScan aptamer-based proteomics platform capable of measuring over 7,000 proteins, went public through a special-purpose acquisition company at a $1.2 billion valuation in September 2021. The company had limited revenue and faced a steep path to profitability.

Then

The stock declined more than 80% from its SPAC listing price within two years as investors soured on pre-revenue life science companies.

Now

SomaLogic merged with Standard BioTools at a fraction of its original valuation, serving as a cautionary tale about taking proteomics platforms public before establishing commercial traction.

Why this matters now

Alamar's heavily oversubscribed IPO at nearly double the planned size suggests investors believe the company has learned from SomaLogic's mistakes — or that the market has fundamentally matured since 2021. Whether Alamar can avoid the same post-IPO decline will depend on converting research interest into recurring revenue.

October 2023 - February 2024

Thermo Fisher acquires Olink Proteomics (2023-2024)

Thermo Fisher Scientific, the world's largest life sciences tools company with over $40 billion in annual revenue, acquired Swedish proteomics company Olink for $3.1 billion in an all-cash deal. Olink's Proximity Extension Assay technology could measure over 5,000 proteins from a single blood sample.

Then

The deal validated proteomics as a commercial category worthy of multi-billion-dollar investment by the industry's largest player.

Now

Thermo Fisher's global distribution network accelerated Olink's platform adoption but also created a dominant incumbent that smaller proteomics companies must compete against.

Why this matters now

This acquisition is the single most important event shaping Alamar's market opportunity. It proved that proteomics platforms command premium valuations, but it also installed a formidable competitor with unmatched distribution power. Alamar's success depends partly on whether the market is large enough for multiple platforms to thrive.